
Recently, the European zzso Agency zzso Committee for zzso Products for Human Use zzso adopted a positive opinion, recommending to grant a marketing authorization for zzso for the treatment of type 2 diabetes zzso zzso is the first human zzso zzso zzso zzso based on the structure of native zzso with zzso properties suitable for zzso zzso In the phase III zzso Effect and Action in Diabetes zzso program, zzso has been shown to lower zzso zzso to the same extent or more than other zzso drugs including zzso zzso determines favorable changes in the global cardiovascular risk profile because its use is associated with weight loss, blood pressure reduction, as well as improvements of several cardiovascular risk zzso zzso is generally well zzso the most frequently reported adverse effect is transient zzso and it does not seems to have significant interactions with medications commonly used for cardiovascular zzso This article reviews, for the practicing zzso the results of the zzso program and explores zzso zzso for cardiovascular prevention in type 2 diabetes zzso 

